P1426EFFECTIVENESS AND SAFETY OF ETELCALCETIDE IN THE LONG TERM IN CLINICAL PRACTICE IN HEMODIALYSIS PATIENTS WITH SECONDARY HYPERPARATHYROIDISM

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Rosa Diaz Campillejo ◽  
Rosa María Ruiz Calero Cendrero ◽  
Lilia Olivera Azevedo ◽  
Jorge Alberto Rodriguez Sabillon ◽  
Belen Ruiz Jimenez ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Side Effects ◽  
Secondary Hyperparathyroidism ◽  
De Novo ◽  
Clinical Manifestations ◽  
Long Term Results ◽  
Phosphate Binders ◽  
Usual Practice ◽  
Usual Clinical Practice

Abstract Background and Aims : Secondary hyperparathyroidism (HPT) is a frequent complication in hemodialysis (HD) patients. Until now we had oral Vit / D analogues and oral Cinacalcet for treatment. The appearance of Etelcalcetide brings new treatment possibilities. Apart from clinical trials there are few long-term results in usual practice. Our goal is to evaluate results with the use of Etelcalcetide after more than a year of treatment in clinical practice of HD. Method We carry out a prospective descriptive study for 15 months with patients with HPT-HD, the ones who were with Cinacalcet and had not responded or had intolerance were changed to Etelcalcetide. Patients without prior treatment with calcimimetics were also included. Treatment with Vit D analogues and phosphate binders is treated according to usual clinical practice. Results We studied 25 HD patients, 12 men and 13 women with a mean age of 59.5 ± 13.6 years, 11 began de novo calcimimetic treatment and in 14 Cinacalcet was modified to Etelcalcetide due to lack of response or poor oral tolerance. Starting dose 2.5 mg post-dialysis, mean final dose 7.5 mg. We observed a reduction of PTH ≥30% in 80% of patients and a decrease ≥50% in 52%, Figure 1 shows the decrease over 15 months. The calcium corrected to albumine (Cac) decreased 4.8% ± 8 compared to baseline. The majority of patients present mild hypocalcemia (Cac between 7.5 and 8.3 mg / dl) and asymptomatic. There are no differences with P. Patients with PTH in range according to KDIGO went from 8% to 63%. No serious clinical manifestations of hypocalcemia or symptoms of digestive intolerance or other side effects appeared.  Conclusion Etelcalcetide in the long term significantly improves the control of HPT in HD with a high safety profile. IV administration facilitates compliance without having followed serious side effects in 15 months of follow-up.

NEUROENDOCRINE TUMORS OF THE PANCREAS: ETIOLOGY, PATHOGENESIS, DIAGNOSIS, AND CURRENT TREATMENT APPROACHES

2018 ◽  
Vol 64 (6) ◽  
pp. 830-839
Author(s):  
Temuri Morgoshiya
Keyword(s):  
Neuroendocrine Tumors ◽  
Clinical Manifestations ◽  
Gastrointestinal Hormones ◽  
Current Treatment ◽  
High Potential ◽  
Long Term Results ◽  
Considerable Part ◽  
Treatment Approaches ◽  
By Products

The overview of literature on modem classification issues, diagnostics and treatments of neuroendocrinal tumors of a pancreas is provided. According to modern views all neuroendocrinal tumors of a pancreas having clinical manifestations (in the form of the syndromes caused by products of specific hormones; increases in level of hormones in blood of patients without clinical manifestations; in the form of signs of existence of volume education in various departments of PZh) and/or the researches (more than 5 mm) revealed by means of beam methods are malignant in the biology as they have high potential to innidiation. In article it is shown that a considerable part of neuroendocrinal tumors of a pancreas are nonfunctioning, i.e. not cosecreting various gastrointestinal hormones and polypeptides in blood and thereof not followed characteristic clinical manifestations. It is noted that diagnostics of neuroendocrinal tumors of a pancreas is extremely difficult task on which solution the choice of a method of treatment and its long-term results depends...

scholarly journals CHRONIC TRAUMATIC DISLOCATION OF II-V METACARPAL BONES: CASE REPORT

2014 ◽  
Vol 2 (4) ◽  
pp. 61-65
Author(s):  
Vladimir Ivanovich Zavarukhin ◽  
Ekaterina Sergeevna Morenko ◽  
Sergey Ivanovich Golyana ◽  
Anton Vladimirovich Govorov
Keyword(s):  
Clinical Manifestations ◽  
Primary Treatment ◽  
Long Term Results ◽  
Carpometacarpal Joints ◽  
Results Of Treatment ◽  
Metacarpal Bones ◽  
High Incidence ◽  
Traumatic Dislocation ◽  
Type Of Injury

Dislocations in the carpometacarpal joints of three-phalanx fingers are rare form of injury. Their clinical manifestations are often veiled by swelling, and radiographs in standard views provide little information, which leads to difficulty in diagnosis and a high incidence of unidentified dislocations in the primary treatment. The article describes the basic provisions of the diagnosis and treatment of this type of injury, a clinical case of surgical treatment of undiagnosed dislocations of II-V metacarpal bones in the acute period, and long-term results of treatment.

LONG-TERM RESULTS WITH THE VACUUM CONSTRICTION DEVICE IN A CLINICAL PRACTICE

1992 ◽  
Vol 85 (Supplement) ◽  
pp. 3S-107
Author(s):  
Michael S. Cookson ◽  
Perry W. Nadig
Keyword(s):  
Clinical Practice ◽  
Long Term Results

The use of Dimexide in the complex treatment of Peyronie's disease

1980 ◽  
Vol 61 (6) ◽  
pp. 53-54
Author(s):  
M. G. Muhamadeev ◽  
M. P. Trofimova
Keyword(s):  
Clinical Manifestations ◽  
Disease Recurrence ◽  
Peyronie’S Disease ◽  
Long Term Results ◽  
Complex Treatment ◽  
Results Of Treatment ◽  
Peyronie's Disease

We observed 9 patients with plastic induration of the penis (Peyronie's disease), 3 of them interrupted treatment. Long-term results of treatment were traced in 6 patients (age - from 48 to 60 years): in 5 patients, complaints and clinical manifestations of disease recurrence were not noted for 2-4 years.

The EORTC randomized trial on three fractions per day and misonidazole (trial no. 22811) in advanced head and neck cancer: long-term results and side effects

1995 ◽  
Vol 35 (2) ◽  
pp. 91-99 ◽  
Author(s):  
Walter Van den Bogaert ◽  
Emmanuel van der Schueren ◽  
Jean-Claude Horiot ◽  
Mario De Vilhena ◽  
Simon Schraub ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Side Effects ◽  
Randomized Trial ◽  
Head And Neck ◽  
Neck Cancer ◽  
Long Term Results ◽  
Advanced Head

Long Term Results of Stereotactic Thalamotomy for Cerebral Palsy

Neurosurgery ◽  
1983 ◽  
Vol 12 (2) ◽  
pp. 195-202 ◽  
Author(s):  
G. Broggi ◽  
L. Angelini ◽  
R. Bono ◽  
C. Giorgi ◽  
N. Nardocci ◽  
...  
Keyword(s):  
Cerebral Palsy ◽  
Side Effects ◽  
Clinical Picture ◽  
Clinical Results ◽  
Long Term Results ◽  
Abnormal Movements ◽  
Average Intelligence ◽  
Stereotactic Thalamotomy

Abstract A group of 33 patients (between 10 and 30 years old and with average intelligence) underwent stereotactic surgery for abnormal movements due to cerebral palsy. Neurological, neurofunctional, and neuropsychological examinations were performed pre- and postoperatively. The length of follow-up ranged between 1 and 4 years. The clinical results are reported and discussed in relation to the targets, the side of the lesion, and the clinical picture. Our data show that better results are obtained in patients with tremor and hyperkinesias; dystonia is improved to a lesser extent, whereas spasticity tends to recur. Operation is more effective for patients with unilateral signs than for patients with bilateral symptoms. The clinical results are stable in time, and the side effects fade away after a few months.

Long Term Continuous Ambulatory Peritoneal Dialysis

1985 ◽  
Vol 5 (2) ◽  
pp. 112-116 ◽  
Author(s):  
Janet Gilmour ◽  
George Wu ◽  
Ramesh Khanna ◽  
Holger Schilling ◽  
Ahmed Mitwalli ◽  
...  
Keyword(s):  
Peritoneal Dialysis ◽  
Clinical Manifestations ◽  
Vitamin B12 Deficiency ◽  
Well Being ◽  
Vitamin D Supplementation ◽  
Drop Out ◽  
Phosphate Binders ◽  
Bone Mineral Mass ◽  
Frequent Use

After five years on CAPD, 10 patients continued to enjoy a good sense of well being and a reasonable quality of life. More women than men survive on CAPD. After 60 months or more of CAPD, the peritoneal membrane continues to function efficiently, both with regards to dialysis of solutes and ultrafiltration of water. Long-term CAPD patients are at risk of developing vitamin B12 deficiency and should receive regular supplements of this vitamin before clinical manifestations develop. Dally administration of I mg of folic acid gives adequate replacement of such losses during peritoneal dialysis. In spite of vitamin D supplementation and phosphate binders, osteitis fibrosa persisted in these patients and they suffered a gradual loss of bone mineral mass. More frequent use of calcium carbonate as phosphate binder and calcium supplement may minimize this complication. Hypertension is well controlled after initiation of CAPD, but recurs after four to five years of this treatment. We conclude that long term CAPD is feasible and that, with reduction in drop-out rates, more patients will remain on this treatment for long periods.

scholarly journals RESTORE: A Prospective Multinational Registry of Patients with Genetically Confirmed Spinal Muscular Atrophy - Rationale and Study Design

2020 ◽  
Vol 7 (2) ◽  
pp. 145-152 ◽  
Author(s):  
Richard S. Finkel ◽  
John W. Day ◽  
Darryl C. De Vivo ◽  
Janbernd Kirschner ◽  
Eugenio Mercuri ◽  
...  
Keyword(s):  
Spinal Muscular Atrophy ◽  
De Novo ◽  
Muscular Atrophy ◽  
Work Productivity ◽  
Healthcare Resource Utilization ◽  
Real World Data ◽  
Activity Impairment ◽  
Survival Status ◽  
Usual Clinical Practice

Background: Dramatic improvements in spinal muscular atrophy (SMA) treatment have changed the prognosis for patients with this disease, leading to important new questions. Gathering representative, real-world data about the long-term efficacy and safety of emerging SMA interventions is essential to document their impact on patients and caregivers. Objectives: This registry will assess outcomes in patients with genetically confirmed SMA and provide information on the effectiveness and long-term safety of approved and emerging treatments. Design and Methods: RESTORE is a prospective, multicenter, multinational observational registry. Patients will be managed according to usual clinical practice. Both newly recruitedSMAtreatment centers and sites involved in existing SMA registries, including iSMAC, Treat-NMD, French SMA Assistance Publique- Hôpitaux de Paris (AP-HP), Cure-SMA, SMArtCARE, will be eligible to participate; de novo; sites already participating in another registry may be included via consortium agreements. Data from patients enrolled in partnering registries will be shared with the RESTORE Registry and data for newly diagnosed patients will be added upon enrollment. Patients will be enrolled over a 5-year period and followed for 15 years or until death. Assessments will include SMA history and treatment, pulmonary, nutritional, and motor milestones, healthcare resource utilization, work productivity, activity impairment, adverse events, quality of life, caregiver burden, and survival. Status: Recruitment started in September 2018. As of January 3, 2020, 64 patients were enrolled at 25 participating sites. Conclusions: The RESTORE Registry has begun recruiting recently diagnosed patients with genetically confirmed SMA, enabling assessment of both short- and long-term patient outcomes.

Sign in / Sign up

Export Citation Format

Share Document